Good start Sci
Like you, I'm no expert either, but apparently it's only the viral shedding (vs) rate we should be worrying about.
It's interesting that in the latest Paterson report, they claim Genocea only achieved a 40% reduction in vs. Your table seems to indicate a Ph.2 trial, whereas Patersons are quoting a later (?) Ph2b results of 40%.
It should also be noted that current acycolvir prescription tablets achieved 76 - 82 % reduction in their trials.
Apparently however, there is a case for using 2 successful medications together to achieve a higher overall result.
It should also be noted that if the AHZ final results are judged successful, this proves the underlying patented platform technology - which then can be put to use against other diseases and cancers.
Long term this may be where MUCH greater value lies for AHZ.
- Forums
- ASX - By Stock
- AVR
- hsv2 final results
hsv2 final results, page-3
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$9.99 |
Change
-0.910(8.35%) |
Mkt cap ! $211.1M |
Open | High | Low | Value | Volume |
$10.50 | $10.79 | $9.30 | $1.477M | 149.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | $9.70 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.99 | 1999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 9.700 |
2 | 146 | 9.600 |
1 | 1050 | 9.500 |
1 | 1500 | 9.420 |
1 | 1050 | 9.400 |
Price($) | Vol. | No. |
---|---|---|
9.990 | 1999 | 1 |
10.000 | 493 | 1 |
10.300 | 1000 | 1 |
10.450 | 357 | 1 |
10.600 | 11800 | 1 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |